PDCD1 and AL amyloidosis: Treatment with anti-PD-1 antibodies resulted in increased cytotoxicity and IFN-γ production of peripheral NK cells from multiple myeloma patients carrying high proportions of PD-1+ NK cells, suggesting that PD-1 could be a target for an immunotherapeutic strategy in EBV-positive PTLD patients [52].